

Please amend the subject patent application as follows:

In the Claims

Please amend Claims 5 and 31 as follows:

5. (Twice Amended) A method of Claim 1 wherein the anti-tumor necrosis factor alpha antibody is administered in [multiple doses] a series of doses separated by intervals of days or weeks.
31. (Twice Amended) A method of treating an autoimmune or inflammatory disease in an individual in need thereof comprising co-administering to the individual methotrexate and [a tumor necrosis factor alpha antagonist to the individual] an agent which interferes with TNF α , TNF α receptor signalling or TNF α synthesis, in therapeutically effective amounts.

REMARKS

Interview

Applicants confirm that an interview with the Examiner to discuss the subject application has been scheduled for Tuesday, June 13, 2000 at 3:00 PM. Applicants thank the Examiner for setting aside this time to discuss the subject application with Applicants.

Paragraph 2: Priority Claim

Applicants acknowledge that the Examiner has determined that Claims 1, 6, 10, 14, 18, 26 and 27 are entitled to a priority date of October 8, 1992, the filing date of U.S. Application No. 07/958,248 (hereinafter referred to as "the '248 application").

The Examiner continues to deny Claims 5, 7-9, 13-17, 21-25 and 28-31 of the claimed priority date of October 8, 1992, the filing date of the '248 application. Applicants traverse.

Under 35 U.S.C. § 120, the claims in a U.S. application are entitled to the benefit of the filing date of an earlier filed U.S. application if the subject matter of the claim is disclosed in the manner provided by 35 U.S.C. § 112, first paragraph in the earlier filed application. In re Scheiber, 199 U.S.P.Q. 782 (C.C.P.A. 1978). The test for sufficiency of support in a parent